Skip to contentF
Fulcrum Therapeutics, Inc.
F
FULCFulcrum Therapeutics, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$26.18M-$26.18MN/M vs Q2 2025 EPS Diluted-$0.34-$0.34N/M vs Q2 2025 Operating Income-$29,310,000N/M Operating Cash Flowderived-$16,039,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fulcrum Therapeutics, Inc. · CIK 1680581 · Engraved from SEC EDGAR
Free Cash Flowderived-$16,147,000N/M ended Jun 30, 2026 · filed Jul 30, 2026 · 30 d after period end